Close Menu

NEW YORK (GenomeWeb) — Invitae announced today that it is partnering with RNAi therapeutics firm Alnylam Pharmaceuticals to provide free genetic testing to improve diagnosis and management of a rare inherited disorder called primary hyperoxaluria.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.